Newswire (Published: Wednesday, November 13, 2019, Received: Wednesday, November 13, 2019, 5:25:44 PM CST)

Word Count: 468

2019 NOV 13 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Researchers detail new data in Oncology - Prostate Cancer. According to news reporting originating from Kagoshima, Japan, by NewsRx correspondents, research stated, “Patients with advanced high-risk prostate cancer (PCa) are prone to have worse pathological diagnoses of positive surgical margins and/or lymph node invasion, resulting in early biochemical recurrence (BCR) despite having undergone radical prostatectomy (RP). Therefore, it is controversial whether patients with high-risk PCa should undergo RP.”

Our news editors obtained a quote from the research from Kagoshima University, “The purpose of this study was to evaluate the efficacy of neoadjuvant chemohormonal therapy (NAC) followed by ‘extended’ RP. A total of 87 patients with high-risk PCa prospectively underwent extended RP after NAC; most of the patients underwent 6 months of estramustine phosphate (EMP) 140 mg twice daily, along with a luteinizing hormone-releasing hormone agonist/antagonist. We developed our surgical technique to reduce the rate of positive surgical margins. We aimed to approach the muscle layer of the rectum by dissecting the mesorectal fascia and continuing the dissection through the mesorectum until the muscle layer of the rectum was exposed. More than 1 year had elapsed after surgery in all 86 patients, with a median follow-up period of 37.7 months. The 3-year BCR-free survival was 74.9%. Multivariate Cox-regression analysis revealed that a positive core ratio of 50% or greater and pathological stage of pT3 or greater were independent predictors for BCR. About 17 of 23 cases received salvage androgen deprivation therapy and concurrent external beam radiotherapy, and showed no progression after the salvage therapies.”

According to the news editors, the research concluded: “NAC concordant with extended RP is feasible and might provide good cancer control for patients with high-risk PCa.”

For more information on this research see: Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study. Japanese Journal of Clinical Oncology, 2019;():. (Oxford University Press - http://www.oup.com/; Japanese Journal of Clinical Oncology - jjco.oxfordjournals.org)

The news editors report that additional information may be obtained by contacting H. Enokida, Dept. of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. Additional authors for this research include Y. Yamada, S. Tatarano, H. Yoshino, M. Yonemori, T. Sakaguchi, H. Nishimura, R. Eura and M. Nakagawa.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1093/jjco/hyz138. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

Kagoshima University
Oxford University Press LLC

Places

Eastern Asia
Japan
Asia
Kagoshima

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Medical Specialties and Practices
            Surgery
            Urology
      Treatments and Therapies
            Surgery